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Familial hypercholesterolaemia (FH; OMIM #143890) is a disorder 
of lipid metabolism inherited in an autosomal dominant form and 
characterised by elevated levels of serum cholesterol.[1] Untreated 
individuals with FH have an increased risk of developing early 
coronary heart disease (CHD), with a >50% cumulative risk of 
fatal or non-fatal CHD by age 50 years in men and at least 30% risk 
in women aged 60 years.[2] The heterozygous form of the disease 
(HeFH) is thought to occur with a frequency of about 1 in 500 
in the population, with the homozygous form (HoFH) occurring 
with a frequency of 1 in 1 000 000,[3] although recent data in 
European populations indicate that the frequency may be higher.[4] 
The prevalence of HeFH in black South African (SA) populations 
is essentially unknown. FH is caused mainly by mutations in 
the low-density lipoprotein receptor (LDLR) (OMIM #606945), 
apolipoprotein B (APOB) (OMIM #107730) and protein convertase 
subtilisin/kexin type 9 (PCSK9) (OMIM #607786) genes, which are 
involved in the regulation of plasma lipid levels. Mutations in the 
LDLR account for the vast majority of the mutations identified in FH 
patients,[2] and recent studies report >1 200 different LDLR mutations 
worldwide.[5] Mutations in the LDLR gene result in the impaired 
uptake or processing of low-density lipoprotein (LDL) particles, 
which results in increased levels of serum LDL cholesterol (LDL-C), 
promoting the development of atheroma and increasing the risk of 
CHD. The LDL particle contains one molecule of apolipoprotein B, 
which is the ligand for the LDL receptor (LDL-R). In carriers of the 
mutant APOB, p.(R3527Q), the affinity of LDL-R for R3527Q-LDL 
is markedly reduced, resulting in the FH phenotype and increased 
risk of CHD.[6] This mutation explains ~5% of cases of FH in 
many European countries,[6] but has not been found in subjects 
of African origin. PCSK9 encodes an enzyme that is involved in 
the post-translational regulation of LDLR by degrading the LDLR 
in the lysosome of the cell, preventing its recycling.[7] Gain-of-
function mutations in this gene such as p.(D374Y) lead to increased 
degradation of the LDLRs, and severe hypercholesterolaemia.[8,9] 
The frequency of this mutation is very low, however, and reported 
to be <2% in patients of European descent with a clinical diagnosis 
of FH.[6]
There is a high prevalence of FH due to founder effect in certain 
isolated populations such as SA Ashkenazi Jews (1 in 72), Lebanese 
Christians (1 in 85), Afrikaners (1 in 100), Tunisians (1 in 165), and 
French Canadians (1 in 270).[3,10] In such populations there is a high 
prevalence of a few mutations causing a large percentage of the FH 
cases observed. For example, three founder mutations, p.(D227E), 
p.(V429M) and p.(D175N), account for ~90% of FH cases among the 
Afrikaners in SA.[11]
There is great value in characterising the FH mutation spectrum of 
a particular population for population screening in order to identify 
potential patients at risk by genetic cascade testing and reduce 
cardiovascular morbidity and mortality. For over a decade, there have 
been no published findings examining the spectrum of mutations 
causing FH in the black SA population. We describe findings in 
16 such patients with a clinical diagnosis of FH.
Methods
Patient samples and DNA extraction
Blood samples from 16 black SA FH patients of different ancestry 
attending the lipid clinic in the Department of Medicine, University 
of the Witwatersrand, Johannesburg, SA, were collected and sent to 
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the Centre for Cardiovascular Genetics, British Heart Foundation 
Laboratories, University College London. The patients consisted of 
3  probands with a clinical diagnosis suggestive of homozygous FH 
and 13 with heterozygous FH. Ethical approval was obtained from the 
Charlotte Maxeke Johannesburg Academic Hospital Human Research 
Ethics Committee (ref. no. M160142), and informed consent was also 
obtained from patients or their representatives. Genomic DNA was 
isolated from buffy coat samples using an adaptation of the salting-
out method described by Miller et al.[12]
High-resolution melting (HRM) and polymerase  
chain reaction (PCR)
The promoter (up to position –298) and coding regions of the LDLR 
gene together with the p.(R3527Q) mutation (part of exon 26) of APOB 
and p.(D374Y) (exon 7) of the PCSK9 gene were screened by HRM. 
Designed oligonucleotide primers for HRM-PCR were used to amplify 
intron-exon junctions and up to 60 base pairs (bp) of the introns of each 
fragment. The primers used were as described by Whittall et al.[13] All 
the HRM runs were performed using the Quanta Accumelt kit (Quanta 
BioSciences, USA) according to the manufacturer’s instructions on 
a Corbett Rotor-Gene6000 system (Corbett Life Science, Australia). 
Owing to their large sizes, exon 4 (381 bp) of the LDLR gene was 
screened by four overlapping PCR fragments and exon 10 (228 bp) by 
two overlapping fragments. Amplification of most of the 3ʹ fragment 
of exon 4, designated as e4.4, was performed on the G-Storm GS4 
thermal cycler (Gene Technologies, UK), as previously described.[13] 
Used as control samples were known mutation-positive samples and 
polymorphic samples, which were run alongside patient samples to 
aid detection of potential mutations in unknown samples, as shown 
previously.[13] Common variants were detected by PCR and restriction 
enzyme digestion, as described by Whittall et al.[13] Characteristic 
HRM profiles of identified variants, difference graph (inset) and 
annotated sequence profile depicting identified variation are shown in 
supplementary Fig. 1 (all supplementary figures and tables are available 
on request from the corresponding author).
Sequencing of PCR fragments
Potential mutant samples revealed by aberrant HRM profiles or 
discord in restriction fragment length polymorphism bands were 
purified using the Illustra GFX PCR DNA and Gel Band Purification 
Kit (both from GE Healthcare Life Sciences, UK), according to the 
manufacturer’s instructions. Samples were sent to Source BioScience 
LifeSciences, Cambridge, UK, for sequencing. Sequence data were 
viewed using the freely downloadable FinchTV version 1.4.0 software 
resource (Geospiza, USA).
Multiplex ligation-dependent probe amplification
Large rearrangements, gross deletions/insertions, copy number 
variations and aberrations were assayed by multiplex ligation probe 
amplification using Kit P062 (MRC-Holland, Netherlands), according 
to the manufacturer’s instructions.
Bioinformatics analysis
The pathogenicity of all identified variants was assessed using open-
access in silico web-based tools. For changes in amino acids, we used 
polymorphism phenotyping (polyPhen; http://genetics.bwh.harvard.
edu/pph2/), Sorting Intolerant From Tolerant (SIFT; http://sift.bii.a-
star.edu.sg/) and Have yOur Protein Explained (http://www.cmbi.ru.nl/
hope/). For variants with potential impact on pre-mRNA splicing, we 
used Berkeley Drosophila Genome Project Splice Site Prediction by 
Neural Network (http://www.fruitfly.org/seq_tools/splice.html) and 
Human Splicing Finder version 2.4.1 (http://www.umd.be/HSF/).
Statistical analysis
All statistical analyses were done using R software for statistical 
computing (v 3.0.1, 2013; R Foundation, Austria) and Stata 12 (Stata-
Corp, USA). Testing for significance of heterogeneity in mutation 
frequencies in mutation-positive and negative groups was based on 
the χ2 and Fisher’s exact tests. Statistical significance was set at a level 
of p<0.05.
Results
Subjects screened in this study were clinically diagnosed FH patients, 
usually with early-onset coronary artery disease (CAD) and/or the 
same manifestation in a first- or second-degree relative. Three of the 
16 probands had a clinical presentation of HoFH and 13 a clinical 
presentation of HeFH (Table 1); 10 of the probands presented with 
the clinical signs of tendon xanthoma, all had corneal arcus, and 4 
had established CAD.
All subjects were screened for mutations causing FH in the LDLR 
gene (coding region, promoter and intron/exon boundaries), the 
APOB gene (part of exon 26) and the PCSK9 gene (exon 7). As shown 
in supplementary Fig. 1, sequencing of the aberrant profiles observed 
in the HRM analysis resulted in the identification of seven different 
LDLR variants with the 6 bp deletion seen in two subjects. This 6 bp 
deletion (FH Cape Town-1), which was first reported in a Xhosa FH 
homozygote,[14] was seen in patients 1 and 5, of Xhosa and Tswana 
origin, respectively. The in-frame deletion of 6 bp in the 3ʹ half of 
exon 2, which encodes the first cysteine-rich repeat, results in the 
elimination of two amino acids, aspartic acid and glycine (p.(D47_
G48del), from the LDLR and is clearly pathogenic. The identified 
LDLR mutations in this study cohort is presented in a schematic plot 
in Fig. 1, with further details shown in supplementary Table 1.
Of the remaining mutations, one missense mutation, p.(L555R), 
and a splice variant, c.1187-25 C>T at the intron 8/exon 9 junction 
(Table 2), have not been reported previously in the SA FH population 
or elsewhere. Patient 10 carried a c.1664 T>G base change, resulting in 
leucine-to-arginine substitution at position 555 of the LDLR protein. 
This patient’s TC level was >9.0 mmol/L. The pathogenicity of a 
leucine-to-proline mutation at the same location caused by a T>C base 
change was described by Sun et al.,[15] using cell extracts from Chinese 
FH patients. As shown in supplementary Fig. 2, the leucine residue at 
this position is highly conserved across several species, and PolyPhen, 
SIFT and MutationTaster predicted the variation to be ‘damaging’.
The second novel variant, c.1187-25C>T, was the only identified 
variant in patient 6, a coloured patient of Tswana origin. The subject 
was 38 years old at the time of DNA blood draw with a TC level of 
10.6 mmol/L, LDL-C 8.1 mmol/L and clinical signs of arcus and 
tendon xanthoma. Although this variant is located 25 bp from the 
start of exon 9, it is predicted to have a proximity effect on the 3ʹ 
acceptor splice (AG) consensus sequence by Human Splicing Finder 
(HSF) algorithms, and to introduce a score variation of –59.6% 
between the wild-type and mutant motif (supplementary Fig. 3A). 
This score variation, which is well under the –30% for MaxEnt 
variation threshold, indicates that the mutation breaks the splice site 
based on literature datasets.[16] The estimated consensus value of the 
mutant sequence differed from the reference wild-type sequence by a 
significant 25% (variation threshold 10%), resulting in a predictable 
break in wild-type branch point due to the mutation and a potential 
alteration of splicing (supplementary Fig. 3B).
Regarding the APOB gene, a silent C-to-T base change at nucleotide 
position 10701 of codon 3567 p.(T3567T) in exon 26 of the APOB 
gene was found in patients 8, 11 and 16, all of whom manifested 
clinical signs of corneal arcus and two of whom had tendon 
xanthomas, and who were of Swazi, Tswana/Sotho and Tswana ori-
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gin, respectively (Table 1). This synonymous variant is presented 
as a rare polymorphism on the exome variant database with T/C 
minor allele frequencies of 0.001 in Europeans and 0.07 in black 
Africans (data not shown). The three carriers had lipid levels that 
were higher than the 4.90 mmol/L diagnostic cut-off value: patient 8 
LDL-C 5.70 mmol/L, patient 11 LDL-C 13.1 mmol/L, and patient 16 
Table 2. Novel nucleotide changes identified in the SA FH probands and in silico prediction of their pathogenicity
Mutation name
Nucleotide 
change Fragment
Protein prediction Splice prediction
Overall/
in silico 
pathogenic 
predictionPolyPhen SIFT MutationTaster BDGP 
Human splice 
finder (%)
p.(L555R) c.1664 T>G Exon 11 Probably 
damaging
Damaging Disease causing n/a n/a Yes
c.1187-25 C>T Intron 8 n/a n/a n/a No effect 59.1 Yes
BDGP = Berkeley Drosophila Genome Project, Release 5, July 2013 (Berkeley, USA); n/a = not applicable.
Fig. 1. Schematic representation of the distribution of identified mutations along the LDLR gene in the SA cohort. Starred variants indicate novel variants. 
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Table 1. Clinical characteristics, ancestry and nucleotide changes identified by molecular genetic analysis in the black SA FH cohort
Patient no. Ancestry Sex YOB
Lipid levels (mmol/L)
HoFH/
HeFH Clinical
Identified mutation(s)
TC TG HDL LDL 1 2
1 Xhosa M 1968 10.4 0.8 1.1 8.9 HeFH Arc, Xan D47_G48del
2 Pedi/N Sotho F 1938 13.1 1.1 1.2 11.4 HeFH CAD, Arc, 
Xan
E408K
3 S Sotho M 1962 13.3 4.2 1.8 9.6 HoFH Arc, Xan c.313+1 G>A R253W
4 Bemba tribe F 1957 9.8 1.1 1.6 7.7 HeFH Arc, Xan
5 Tswana F 1964 12.7 0.8 1.7 10.6 HeFH Arc, Xan D47_G48del
6 Tswana + ‘coloured’ F 1975 10.6 0.6 2.2 8.1 HeFH Arc, Xan c.1187-25C>T
7 Tswana + N Sotho F 1940 10.8 0.4 1.3 9.2 HeFH Arc, Xan
8 Swazi F 1938 8.3 1.5 1.9 5.7 HeFH Arc
9 S Sotho M 1942 7.7 1.7 0.9 6.0 HeFH CAD, Arc
10 African F N/A 9.0 N/A N/A N/A HeFH N/A L555R
11 Tswana + N Sotho F 1963 14.9 0.8 1.4 13.1 HoFH Arc, Xan
12 N Sotho F 1937 9.9 3.0 1.1 7.4 HeFH CAD, Arc, Xan
13 Zulu M 1956 7.5 2.0 1.2 5.4 HeFH CAD, Arc
14 Zulu F 1950 10.1 1.9 1.6 7.6 HeFH Arc R814Q
15 S Sotho + Tswana F 1943 7.3 2.6 1.5 4.6 HeFH Arc
16 Tswana M 1992 20.4 0.4 1.2 19.0 HoFH Arc, Xan
YOB = year of birth; F = female; M = male; TC = total serum cholesterol; TG = triglyceride; HDL = high-density lipoprotein; Arc = corneal arcus; Xan = tendon xanthoma; N/A = not available.
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LDL-C 19.0 mmol/L. Two of these subjects had clinical HoFH, and 
while it seems unlikely that this variant caused FH in these subjects, 
samples of relatives were not available to carry out co-segregation 
analysis of this variant and plasma lipid levels.
The causative mutations were only found in one of the three 
patients with a clinical diagnosis suggestive of HoFH. To confirm 
the sensitivity of the HRM method, FH patients of Afrikaner, Indian 
and different European ancestry were also analysed (supplementary 
Tables 1 - 3). Overall nine different point mutations and three 
different gross deletions in the LDLR gene were found, including two 
of the founder mutations previously reported in the SA population, 
namely p.(D227E) and p.(V429M), and one reported in subjects from 
the Indian subcontinent, p.(P685L). The common APOB mutation 
p.(R3527Q) was found in one patient.
Discussion
The black African SA patients screened in this study were from nine 
tribal groups, with a comparison group of non-African subjects of 
Caucasian-Afrikaner, Caucasian-European and Indian ancestry. In 
the 16 black African subjects, eight predicted FH-causing mutations 
were identified. Several mutations previously reported in black 
African subjects were seen,[11] and two novel variants were identified. 
Both novel variants were predicted to be pathogenic by in silico 
analysis, but while co-segregation studies in the relatives of these 
patients would be valuable, family members were unavailable for 
such studies.
The relatively low detection rate raises concern about the sensitivity 
of the HRM method used. While we have previously demonstrated 
that HRM is a sensitive and specific technique[13] for mutation 
detection in FH patients, and with detection of a wide range of 
LDLR point mutations and gross deletions in the comparison group 
examined, we acknowledge that next-generation sequencing (NGS) 
is now the preferred method of choice for molecular diagnosis. This 
work was commenced in 2013 when such methods were not widely 
available, and NGS remains an expensive technique and beyond the 
funds available for this research project. Also, while we screened the 
regions of the PCSK9 and APOB genes known to contain pathogenic 
mutations in subjects of European ancestry,[13] it is possible that a 
proportion of patients may have mutations in the exons not covered 
here. While pathogenic variants in other regions of APOB have 
been reported,[17] these are very rare. Similarly, gain-of-function 
FH-causing mutations in PCSK9 are also rare, for example accounting 
for <2% of FH patients in the UK. While loss-of-function variants 
have been reported in African American individuals (with low 
cholesterol levels), no gain-of-function variants have been reported 
in this population group as far as we are aware. We therefore estimate 
that complete coverage of these two genes may at best have increased 
the overall detection rate by 2 - 3%. Failure to identify the causative 
mutation in over half of the patients and in two-thirds with a clinical 
presentation of HoFH is therefore surprising, and may suggest that 
in these subjects the FH phenotype may be caused by novel loci, for 
example in the STAP1 gene,[18] which was not examined here.
It has recently been reported that in a considerable proportion 
of European subjects with a clinical diagnosis of FH for which no 
causative mutation can be found, a polygenic cause is the most likely 
explanation for their elevated LDL-C levels.[19] While this is a possible 
explanation for the cause of the FH phenotype in a proportion 
of our no-mutation patients, unfortunately the single-nucleotide 
polymorphisms used in the LDL-Gene score[19] in European subjects 
have not been validated for use in individuals of African origin, 
and owing to frequency differences and differences in linkage 
disequilibrium, it is likely that a different set of single-nucleotide 
polymorphisms would be needed.
The identification of these seven different FH-causing variants 
in our black African subjects underlines the heterogeneity of the 
cases of the FH phenotype in these subjects and demonstrates that 
comprehensive sequencing of the known FH-changing genes will 
be required to enable the efficient identification of patients with 
a monogenic cause of their phenotype for cascade testing of their 
relatives, so that early intervention with lipid-lowering statin therapy 
can be offered.
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